Review: taking Ipratropium bromide and Budesonide together


Summary

Drug interactions are reported among people who take Ipratropium bromide and Budesonide together. This review analyzes the effectiveness and drug interactions between Ipratropium bromide and Budesonide. It is created by eHealthMe based on reports of 2,002 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Ipratropium bromide and Budesonide >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Ipratropium Bromide

Ipratropium bromide has active ingredients of ipratropium bromide. It is often used in chronic obstructive pulmonary disease. (latest outcomes from Ipratropium bromide 7,377 users)

Budesonide

Budesonide has active ingredients of budesonide. It is often used in crohn's disease. (latest outcomes from Budesonide 6,494 users)

On Aug, 28, 2016

2,002 people who take Ipratropium Bromide, Budesonide are studied.


Number of reports submitted per year:

Ipratropium bromide and Budesonide drug interactions.

Drug effectiveness over time:

Ipratropium Bromide:
  • < 1 month: 100.0% - (1 of 1 people)
  • 1 - 6 months: 33.0% - (1 of 3 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 1 people)
  • 10+ years: 0.0% - (0 of 1 people)
  • not specified: 0.0% - (0 of 0 people)
Budesonide:
  • < 1 month: 100.0% - (1 of 1 people)
  • 1 - 6 months: 33.0% - (1 of 3 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 2 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Ipratropium Bromide:
  • female: 66.0% - (2 of 3 people)
  • male: 20.0% - (1 of 5 people)
Budesonide:
  • female: 66.0% - (2 of 3 people)
  • male: 20.0% - (1 of 5 people)

Drug effectiveness by age:

Ipratropium Bromide:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 100.0% - (1 of 1 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 100.0% - (1 of 1 people)
  • 60+: 20.0% - (1 of 5 people)
Budesonide:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 100.0% - (1 of 1 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 100.0% - (1 of 1 people)
  • 60+: 20.0% - (1 of 5 people)

Most common drug interactions over time *:

< 1 month:
  • sepsis
  • pneumonia
  • dyspnoea
  • multi-organ failure
  • haematoma
  • colitis
  • pleural effusion
  • escherichia infection
  • gastrointestinal haemorrhage
  • peritonitis
1 - 6 months:
  • haemoptysis
  • adrenal mass
  • atrial fibrillation
  • cardiac failure congestive
  • hypoglycaemia
  • hypotension
  • respiratory tract infection
  • abdominal distension
  • anxiety
  • arthralgia
6 - 12 months:
  • dyspnoea
  • abdominal pain
  • acute sinusitis
  • alopecia
  • anaemia
  • arthropathy
  • asthma
  • blood alkaline phosphatase increased
  • blood creatine phosphokinase abnormal
  • breast mass
1 - 2 years:
  • dyspnoea
  • oedema peripheral
  • urinary tract infection
  • arthralgia
  • cellulitis staphylococcal
  • deep vein thrombosis
  • hypotension
  • lung infection
  • osteoarthritis
  • pain in extremity
2 - 5 years:
  • bacterial infection
  • choking
  • cough
  • depression
  • fatigue
  • increased upper airway secretion
  • pneumonia
  • angina pectoris
  • anxiety
  • asthenia
5 - 10 years:
  • cardiac arrest
  • dyspnoea
  • chronic obstructive pulmonary disease
  • infection
  • left ventricular failure
  • pneumonia
  • anxiety
  • asthenia
  • atrial fibrillation
  • chest discomfort
10+ years:
  • infertility female
not specified:
  • dyspnoea
  • pneumonia
  • asthma
  • cough
  • nausea
  • asthenia
  • drug ineffective
  • chronic obstructive pulmonary disease
  • pain
  • fatigue

Most common drug interactions by gender *:

female:
  • dyspnoea
  • asthma
  • pneumonia
  • nausea
  • cough
  • headache
  • vomiting
  • chronic obstructive pulmonary disease
  • oedema peripheral
  • pain
male:
  • dyspnoea
  • pneumonia
  • asthenia
  • cough
  • pyrexia
  • drug ineffective
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • respiratory failure

Most common drug interactions by age *:

0-1:
  • death
  • bronchopulmonary dysplasia
  • infusion related reaction
  • respiratory distress
  • retching
  • tachycardia
  • vomiting
  • hyperhidrosis
  • hypoxia
  • oxygen saturation decreased
2-9:
  • oxygen saturation decreased
  • cough
  • respiratory syncytial virus infection
  • dyspnoea
  • pyrexia
  • pneumonia
  • respiratory failure
  • asthma
  • drug ineffective
  • lung disorder
10-19:
  • asthma
  • neutropenia
  • pruritus
  • asthma aggravated
  • convulsion
  • drug ineffective
  • dyskinesia
  • fatigue
  • hypoaesthesia
  • hyponatraemia
20-29:
  • cough
  • dyspnoea
  • fatigue
  • asthma
  • wheezing
  • drug exposure during pregnancy
  • pyrexia
  • dry mouth
  • gastrooesophageal reflux disease
  • headache
30-39:
  • nausea
  • headache
  • anxiety
  • asthenia
  • thrombocytopenia
  • hypokalaemia
  • vision blurred
  • paraesthesia
  • pyrexia
  • dyspnoea
40-49:
  • asthma
  • headache
  • vomiting
  • dyspnoea
  • oedema peripheral
  • nasopharyngitis
  • nausea
  • wheezing
  • chest pain
  • dyspepsia
50-59:
  • dyspnoea
  • asthma
  • pneumonia
  • arthralgia
  • dizziness
  • fatigue
  • nausea
  • chronic obstructive pulmonary disease
  • pain
  • headache
60+:
  • dyspnoea
  • pneumonia
  • chronic obstructive pulmonary disease
  • drug ineffective
  • nausea
  • hypotension
  • renal failure acute
  • cough
  • respiratory failure
  • asthenia

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Ipratropium bromide and Budesonide?

Can you answer these questions?

More questions for: Ipratropium bromide, Budesonide

You may be interested in these reviews

More reviews for: Ipratropium bromide, Budesonide

On eHealthMe, Ipratropium bromide (ipratropium bromide) is often used to treat chronic obstructive pulmonary disease. Budesonide (budesonide) is often used to treat crohn's disease. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.